Printer Friendly

EVRO FINANCIAL SUBSIDIARY ANNOUNCES HEIGHTENED INTEREST IN ADVANCED BREAST EXAMINATION TECHNOLOGIES

 TAMPA, Fla., March 4 /PRNewswire/ -- D. Jerry Diamond, chairman/CEO of EVRO Financial Corp. (NASDAQ: EVRO), announced today that its subsidiary, Lintronics Technologies, Inc., has experienced a heightened interest in its two advanced breast examination technologies, the LINTRO-SCAN(R) and the MAMMO-SCAN(R), due to a recent Canadian study which questioned the effectiveness of x-ray in detecting breast cancer in women under 50 years of age. The findings of this study were confirmed by a recently published Swedish study and in light of these findings the National Cancer Institute convened a conference to discuss the effectiveness of mammography and to review screening recommendations.
 Diamond indicated that these studies had stimulated response from physicians seeking supportive procedures for their younger patients due to the staggering statistics that nearly 12,000 women under the age of 40 develop breast cancer each year. "Interest in adjunctive procedures to mammography which use no radiation are at an all time high," Diamond reported, "and with the LINTRO-SCAN(R) we have a technology which proves itself daily as a test to assist mammography with conditions that have long posed problems like the dense breasts of younger patients and augmented breasts.
 "While we have several examples where the LINTRO-SCAN(R) identified abnormalities which were missed by mammography, let me publicly state that we are not out to replace mammography," Diamond said. "The value of the LINTRO-SCAN(R) is its adjunctive role complementing mammography in dense and augmented breasts and in breast evaluation of high risk women between scheduled mammograms. This is why physicians are interested and units are selling."
 "Patients having the test have become some of the best advocates of the LINTRO-SCAN(R)," reports Nancy Hemby, RN, vice president of training. "We stress adherence to mammography guidelines and monthly self exams and our patients recognize that this technology was designed to be sensitive to the changing healthcare needs of women."
 The corporate offices of EVRO are located at 10002 Princess Palm Ave., Suite 304, Tampa, FL 33619.
 -0- 3/4/93
 /CONTACT: D. Jerry Diamond, chairman and CEO, or Dominick R. Maggio, vice president of public relations of EVRO Financial Corp., 813-623-6044/
 (EVRO)


CO: EVRO Financial Corp.; Lintronics Technologies, Inc. ST: Florida IN: HEA SU:

JB-AW -- FL004 -- 2864 03/04/93 09:59 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 4, 1993
Words:378
Previous Article:CITROEN AX DIESEL WITH LUCAS ENGINE MANAGEMENT SYSTEM SETS NEW WORLD ECONOMY RECORD
Next Article:HANSEN NATURAL CORP. (HANS) ANNOUNCES EXTENSION OF CLASS A WARRANTS
Topics:


Related Articles
EVRO FINANCIAL ANNOUNCES LETTER OF INTENT
EVRO FINANCIAL ANNOUNCES ACQUISITION
U.S. NAVY PLACES $1 MILLION ORDER FOR LORAD MAMMOGRAPHY AND BIOPSY SYSTEMS
FDA ADVISORY PANEL UNANIMOUSLY RECOMMENDS APPROVAL FOR ATL ULTRASOUND
FDA APPROVES ATL ULTRASOUND FOR BREAST CANCER MANAGEMENT
FDA APPROVES ATL ULTRASOUND FOR BREAST CANCER MANAGEMENT
Leading Massachusetts Health Insurance Companies Approve MRI Breast Imaging Tests for Reimbursement;
University of Texas Completion of 200 Test Scans with Advanced Mammography's Dedicated Breast Imaging System;
University of Virginia's Clinical Research Services Evaluate HumaScan Adjunctive Breast Disease Screening Device
HumaScan Inc. Reports Third Quarter Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters